| Primary information |
|---|
| OV_ID | OV_394 |
| Virus Name | Herpes simplex virus |
| Strain | ICP10PK |
| Virus type | DNA |
| Virus family | Herpesviridae |
| Modification in virus genome | Deletion mutant with R1 domain poorly functional in HSV-1 |
| Virus alone | No |
| Virus in combination iwth drug/radiation | Viral strain in combination with SP600125 (100 μM) |
| Immune gene induction in virus genome | No |
| Source of cell line | ATCC |
| Origin of cell line | Human malignant melanoma cell lines |
| Cell line | A2058 |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | Trypan blue staining |
| In-vitro virus concentration | 1 MOI |
| In-vitro result | 35% cancer cell death at 48 hours after post infection |
| Model organism | No |
| In-vivo virus concentration | No |
| In-vivo toxicity | NA |
| In-vivo result | No response |
| Mode of delivery | NA |
| Pathway induction | Induces JNK/c-Jun, autophagy and pyroptosis activation |
| Immunogenic effect | ICP10PK upregulates of caspase-1, -4, and -5, the cytokines IL-1alpha, IL-1beta, IL-6, IL-8, IL-12, TNF-alpha, lymphotoxina and GM-CSF, and mitogen-activated protein kinases (MAPKs) involved in both PCD and inflammatory processes |
| Clinical trial | NA |
| PMID | 26602205 |